Active surveillance in prostate cancer management: where do we stand now?
- PMID: 34025851
- PMCID: PMC8130493
- DOI: 10.5114/aoms.2019.85252
Active surveillance in prostate cancer management: where do we stand now?
Abstract
Prostate cancer (PCa) is the most common cancer in men, with a steadily rising incidence, affecting on average one in six men during their lifetime. The increase in morbidity is related to the increasing overall life expectancy, prostate-specific antigen testing, implementation of new molecular markers for cancer detection and the more frequent application of multiparametric magnetic resonance imaging. There is growing evidence demonstrating that active surveillance (AS) is an alternative to immediate intervention in patients with very low- and low-risk prostate cancer. Ongoing reports from multiple studies have consistently demonstrated a very low rate of metastases and prostate cancer specific mortality in selected cohorts of patients. As a matter of fact, AS has been adopted by many institutions as a safe and effective management strategy. The aim of our review is to summarize the contemporary data on AS in patients affected with PCa with the intention to present the most clinically useful and pertinent AS protocols.
Keywords: active surveillance; molecular markers; multiparametric magnetic resonance imaging; prostate cancer.
Copyright: © 2020 Termedia & Banach.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging.Rev Urol. 2017;19(2):77-88. doi: 10.3909/riu0757a. Rev Urol. 2017. PMID: 28959144 Free PMC article.
-
The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.J Urol. 2020 May;203(5):910-917. doi: 10.1097/JU.0000000000000693. Epub 2019 Dec 11. J Urol. 2020. PMID: 31825297 Clinical Trial.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Multiparametric magnetic resonance imaging: Current role in prostate cancer management.Int J Urol. 2016 Jul;23(7):550-7. doi: 10.1111/iju.13119. Epub 2016 May 17. Int J Urol. 2016. PMID: 27184019 Review.
-
Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.Anticancer Agents Med Chem. 2018;18(7):925-930. doi: 10.2174/1871520618666180105105413. Anticancer Agents Med Chem. 2018. PMID: 29303080
Cited by
-
Predicting the Diagnosis of Prostate Cancer with a Novel Blood-Based Biomarker: Comparison of Its Performance with Prostate-Specific Antigen.Cancers (Basel). 2024 Jul 23;16(15):2619. doi: 10.3390/cancers16152619. Cancers (Basel). 2024. PMID: 39123347 Free PMC article.
-
Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.Int J Mol Sci. 2025 Jun 4;26(11):5386. doi: 10.3390/ijms26115386. Int J Mol Sci. 2025. PMID: 40508192 Free PMC article. Review.
-
A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality.Res Rep Urol. 2022 May 11;14:203-217. doi: 10.2147/RRU.S358169. eCollection 2022. Res Rep Urol. 2022. PMID: 35586706 Free PMC article.
References
-
- Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105:1050–8. - PubMed
-
- National Institute for Health and Care Excellence . Prostate cancer: diagnosis and management. NICE; 2014. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials